ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, ...
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India
Their 3 main product categories are:
- Home, personal care, and performance chemicals
- Textile specialty chemical
- Animal health and nutrition
The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT...
Market Position and Growth Drivers:
Protagonist Therapeutics NASDAQ:PTGX is poised for substantial growth, with its recent inclusion in the S&P Small Cap 600 likely attracting significant institutional buying and boosting its stock price.
Strategic Partnership:
The company's partnership with Takeda to develop and market Rusfertide has already resulted in a $300...
Innovation and Market Leadership:
Twist Biosciences NASDAQ:TWST , a leader in synthetic DNA products, is set for substantial growth with its new Express Genes service, offering NGS-verified genes in just five to seven business days. This innovation is expected to strengthen Twist's market position and dominance.
Growth Forecast and Market Expansion:
The company...
Disclosure: As of 6/24 I am long SIGA Technologies NASDAQ:SIGA
SIGA Technologies is a bio pharmaceuticals company that is in the public health market. They develop and sell products to treat Smallpox, Ebola, and other public health threats.
Management Effectiveness: The company has been consistently profitable since 2018, with margins averaging 30%-40% in...
DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on...
Clinical Milestone:
Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win."
Strategic Collaborations:
Nurix is also...
Sharing an intermediate view of the EW count options for XBI.
The short-term bullish range is $97-$98.
The short-term bearish target ranges are $89 - $88.50 and $87.
The bearish count, in red, drops the price to $81ish as first support. If, $81 range does not hold, $72 is the C wave target.
In the meantime, I anticipate a lot of chop in the range from...
Dark Pools are accumulating some biotechnology stocks for mutual funds and ETFs based on this new technology. HFTs are chasing this accumulation.
NASDAQ:STOK is now near the price when more professional traders are likely to swing trade. It has a very high Percentage of Shares Held by Institutions and the bottom is completed. It may be a potential candidate...
GEVO is priming for a big comeback. It's a sleeping giant. Has been on a down trend close to 2 decades.
For pennies on the dollar, this is an opportunity equivalent to mining bitcoin in 2009 and holding your bag for a very long time.
This is a long-term hold. 5+ years.
Someone believed in the Biofuels technology at one point where a share was traded over...
Watch the clip from the ALL In Podcast.
Daily and Weekly Double bottom + a renewed sense of urgency screams BOOM to me????
The public outcry will be huge!
If you missed the 10X call on VKTX:
Then analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week,
I would consider purchasing the 75usd strike price Calls with
an expiration date of 2024-5-17,
for a premium of approximately $2.57.
If these options prove to be profitable prior to the earnings release,...
After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend.
**Potential Scenarios:**
**Scenario 1: Triangular Consolidation (Orange)**
ATAI may undergo consolidation...
Gilead Sciences (GILD): NASDAQ:GILD
We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at...
Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is...
Pfizer (PFE): NYSE:PFE
At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation...
TSXV:NRX Nurexone Biologic leading biotech plays in 2024 with several recent developments from newly uplisting on the OTC, leasing agreement until 2028 of a state-of-the-art facility on a University campus in Israel to beginning clinical trials shortly.
